الصفحة الرئيسية>>Signaling Pathways>> Membrane Transporter/Ion Channel>> Monocarboxylate Transporters>>7ACC2

7ACC2

رقم الكتالوجGC14642

7ACC2 هو مثبط قوي لنقل أحادي الكربوكسيل (MCT) مع IC لـ 11 نانومتر لتثبيط [14 درجة مئوية] تدفق اللاكتات7ACC2 هو أيضًا مثبط قوي لنقل بيروفات الميتوكوندريا7ACC2 هو عامل مضاد للسرطان من خلال تثبيط تدفق اللاكتات

Products are for research use only. Not for human use. We do not sell to patients.

7ACC2 التركيب الكيميائي

Cas No.: 1472624-85-3

الحجم السعر المخزون الكميّة
5mg
81٫00
Ship Within 10-14 Days
10mg
135٫00
Ship Within 10-14 Days
50mg
461٫00
Please Inquire
100mg
738٫00
Please Inquire

Tel:(909) 407-4943 Email: sales@glpbio.com


مراجعات العميل

بناء على آراء العملاء.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

7ACC2 is a new potent MCT inhibitor with IC50 of 11 nM for inhibition of [14C]-lactate influx; new antitumor treatment targeting lactate transport in cancer cells.IC50 value: 11 nM ([14C]-lactate influx) [1]Target: MCT inhibitor; lactate transport inhibitor7ACC2 did not influence the prothrombin time which, together with a good in vitro ADME profile, supports the potential of this new family of compounds to act as anticancer drugs through inhibition of lactate flux.

References:
[1]. Draoui N, et al. Synthesis and pharmacological evaluation of carboxycoumarins as a new antitumor treatment targeting lactate transport in cancer cells. Bioorg Med Chem. 2013 Nov 15;21(22):7107-17.

مراجعات

Review for 7ACC2

Average Rating: 5 ★★★★★ (Based on Reviews and 18 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for 7ACC2

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.